Ponezumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | beta-amyloid |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6552H10158N1730O2090S52 |
| Molar mass | 148272.48 g·mol−1 |
| (what is this?) (verify) | |
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.
Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.